Elizabeth graduated from Oxford in 2009, and began working in start-up biotech company Chronos Therapeutics Ltd developing a platform screening technology with the aim of repurposing drugs for age-related diseases including: Parkinson's Disease, amyotrophic lateral sclerosis and osteoporosis.
During her time in industry Elizabeth worked in all areas of the company including designing the pre-clinical research and development program and managing the company patent portfolio. Through the development of candidate drugs using a phenotypic drug screening platform Elizabeth also acquired experience of pharmacokinetics, pharmacodynamics and biomarkers, as well as, the development of disease models and nutraceutical product development.
Whilst working at Chronos, Elizabeth also worked part time for the Centre for Advancement of Sustainable Medical Innovations (CASMI) which aims to work with a wide range of stakeholders to develop new models for medical innovation. This gave her the opportunity to study pharmaceutical and medical device development as a whole and research promising areas for development in the future, such as adaptive licensing, stratified medicine, cell therapy and regenerative medicine.
Elizabeth has a broad academic background encompassing biochemistry, molecular biology, bio-nanotechnology, neuropharmacology and molecular oncology. She now works on cases covering a range of life science subject matter, maintaining a particular interest in bio-nanotechnology, drug repurposing and regenerative medicine.
Elizabeth joined J A Kemp in 2015.
University of Oxford, Masters Degree in Molecular and Cellular Biochemistry
Certificate in Intellectual Property Law, Queen Mary, University of London
Student member of the Chartered Institute of Patent Attorneys (CIPA)